

AbbVie hits a new 52-week high after beating Q3 2026 earnings estimates, raising its full-year guidance, and boosting its dividend.
You can purchase shares of AbbVie (NYSE:ABBV) through any online brokerage.
Other companies in AbbVie’s space includes: Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX), Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Moderna Inc (NASDAQ:MRNA).
AbbVie has a consensus price target of $275.15.
The stock price for AbbVie (NYSE: ABBV) is $295.1802 last updated November 2, 2026 at 6:06 AM EST.
There are no upcoming dividends for AbbVie.
AbbVie does not have any upcoming earnings scheduled.
There is no upcoming split for AbbVie.
AbbVie is in the Health Care sector and Biotechnology industry. They are listed on the NYSE.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several...